Clinical Letter
Asthma-COPD Overlap – A Gateway to Biological Treatment
Alicia Padilla-Galo
, Marina Rubio Moreno, Borja Valencia Azcona
Corresponding author
Servicio de Neumología, Hospital Universitario Costa del Sol, Spain
Read
74
Timeswas read the article
29
Total PDF
45
Total HTML
Share statistics
array:22 [ "pii" => "S0300289624004095" "issn" => "03002896" "doi" => "10.1016/j.arbres.2024.10.006" "estado" => "S100" "fechaPublicacion" => "2024-10-29" "aid" => "3674" "copyright" => "SEPAR" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S030028962400406X" "issn" => "03002896" "doi" => "10.1016/j.arbres.2024.10.003" "estado" => "S100" "fechaPublicacion" => "2024-10-29" "aid" => "3671" "copyright" => "The Authors" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Effect of the Antibody-mediated Immune Responses on COPD, Asthma, and Lung Function: A Mendelian Randomization Study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2751 "Ancho" => 2633 "Tamanyo" => 566970 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Causal estimates of bidirectional MR between antibody-mediated immune responses, COPD, asthma, emphysema, bronchiectasis, FEV1, FVC, and FEV1/FVC. Top: Estimates from the IVW analysis of antibody-mediated immune responses on COPD, asthma, emphysema, bronchiectasis, FEV1, FVC, and FEV1/FVC. Bottom: Estimates from the IVW analysis of COPD, asthma, emphysema, bronchiectasis, FEV1, FVC, and FEV1/FVC on antibody-mediated immune responses. The antibody-mediated immune responses features underlined in red were related to COPD, asthma, FEV1, and FVC. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; MR: Mendelian randomization.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Xu Guixing, Liu Yilin, Fan Huaying, Liang Fanrong, Li Dehua" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Xu" "apellidos" => "Guixing" ] 1 => array:2 [ "nombre" => "Liu" "apellidos" => "Yilin" ] 2 => array:2 [ "nombre" => "Fan" "apellidos" => "Huaying" ] 3 => array:2 [ "nombre" => "Liang" "apellidos" => "Fanrong" ] 4 => array:2 [ "nombre" => "Li" "apellidos" => "Dehua" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S030028962400406X?idApp=UINPBA00003Z" "url" => "/03002896/unassign/S030028962400406X/v1_202410291634/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "S0300289612000968" "issn" => "03002896" "doi" => "10.1016/j.arbres.2012.02.017" "estado" => "S200" "fechaPublicacion" => "2013-05-08" "aid" => "621" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "ret" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 348 "formatos" => array:2 [ "HTML" => 82 "PDF" => 266 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "WITHDRAWN: Respiratory Muscle Assessment in Predicting Extubation Outcome in Patients With Stroke" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonio A.M. Castro, Felipe Cortopassi, Russell Sabbag, Luis Torre-Bouscoulet, Claudia Kümpel, Elias Ferreira Porto" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Antonio A.M." "apellidos" => "Castro" ] 1 => array:2 [ "nombre" => "Felipe" "apellidos" => "Cortopassi" ] 2 => array:2 [ "nombre" => "Russell" "apellidos" => "Sabbag" ] 3 => array:2 [ "nombre" => "Luis" "apellidos" => "Torre-Bouscoulet" ] 4 => array:2 [ "nombre" => "Claudia" "apellidos" => "Kümpel" ] 5 => array:2 [ "nombre" => "Elias Ferreira" "apellidos" => "Porto" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289612000968?idApp=UINPBA00003Z" "url" => "/03002896/unassign/S0300289612000968/v2_201305131254/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Clinical Letter</span>" "titulo" => "Asthma-COPD Overlap – A Gateway to Biological Treatment" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">To the Director</span>," "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Alicia Padilla-Galo, Marina Rubio Moreno, Borja Valencia Azcona" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Alicia" "apellidos" => "Padilla-Galo" "email" => array:1 [ 0 => "aliciapadillagalo@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Marina" "apellidos" => "Rubio Moreno" ] 2 => array:2 [ "nombre" => "Borja" "apellidos" => "Valencia Azcona" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Neumología, Hospital Universitario Costa del Sol, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1967 "Ancho" => 3000 "Tamanyo" => 227121 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Pulmonary function evolution.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Asthma-COPD overlap (ACO) involves patients with asthma-like characteristics who have been exposed to COPD risk factors and developed persistent airflow obstruction (PAO).<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> These patients typically have more symptoms, lower quality of life, and a higher risk of exacerbations than COPD patients. According to the SEPAR consensus on ACO,<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> diagnosis is made in patients ≥35 years old, with ≥10 pack-years smoking history, PAO, and either a current asthma diagnosis, a highly positive bronchodilator test, or elevated blood eosinophilia. In terms of treatment, ACO patients have a poorer response to inhaled corticosteroids than asthma patients, but monoclonal antibodies approved for asthma can also be used, although real-world data on benralizumab is limited.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We present the case of a 54-year-old man ex-smoker with a 60 pack-year history, diagnosed with COPD and receiving triple inhalation therapy at a COPD clinic. He has undergone four surgeries for nasal polyposis, had PAO in all follow-ups, a positive skin test for dog and cat epithelia, and 6% blood eosinophilia (historically always above 460<span class="elsevierStyleHsp" style=""></span>eosinophils/μl). He had dyspnea with mMRC grade 1, wheezing since age 30, 5–6 exacerbations per year in recent years treated with antibiotics and oral corticosteroids, including two hospitalizations in the last year. He was referred to our asthma clinic, where an obstructive spirometry with a negative bronchodilator test (FEV1/FVC: 45%, FEV1: 48%), FeNO 99<span class="elsevierStyleHsp" style=""></span>ppb, IgE 259, and eosinophilia of 8.7% (700<span class="elsevierStyleHsp" style=""></span>eosinophils/μl) were observed. He was diagnosed with ACO, inhalation therapy was adjusted, and due to persistent poor control, benralizumab treatment was initiated. Over the three years of follow-up after starting benralizumab, he reported significant clinical improvement (ACT 23), requiring only one course of antibiotics and oral corticosteroids. Additionally, his nasal polyposis improved, with no further surgeries needed. FeNO decreased to 24, and he still has PAO, but with an FEV1 >80%. See <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Given the clinical features consistent with asthma, recurrent nasal polyposis, frequent exacerbations despite appropriate treatment, and elevated T2 markers, along with COPD-related features such as a 60 pack-year smoking history and PAO, the patient was diagnosed with ACO according to the SEPAR consensus criteria.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> The lack of a standardized and universally accepted definition of ACO makes diagnosis complex, often leading to underdiagnosis. Furthermore, treatment options are limited as there are no specific biomarkers or standardized therapies. Clinical trials for biologic drugs in severe asthma excluded smokers, while COPD trials excluded patients with asthma features, leaving ACO patients unrepresented. This has resulted in ACO patients being less likely to receive biologics compared to those with severe asthma. Thus, real-world studies on the use of biologics in ACO are essential, though currently limited. The main real-world studies in ACO<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">3,4</span></a> focused on omalizumab, mepolizumab, reslizumab, and dupilumab. A recent study with benralizumab,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> using insurance database records in the US, lacked clinical or spirometric criteria, introducing potential selection bias. Nevertheless, all real-world studies confirm biologics’ effectiveness in ACO. This case highlights the clinical improvement and remarkable lung function response with benralizumab, emphasizing the need for accurate diagnosis and specific precision medicine treatments.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflict of Interests</span><p id="par0020" class="elsevierStylePara elsevierViewall">The authors state that they have no conflict of interests.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of Interests" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1967 "Ancho" => 3000 "Tamanyo" => 227121 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Pulmonary function evolution.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "GINA 2024. Available from: <a target="_blank" href="https://ginasthma.org/">https://ginasthma.org</a> [accessed 20.09.23]." ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Plaza" 1 => "F. Álvarez" 2 => "M. Calle" 3 => "C. Casanova" 4 => "B.G. Cosío" 5 => "A. López-Viña" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2017.04.002" "Revista" => array:7 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2017" "volumen" => "53" "numero" => "8" "paginaInicial" => "443" "paginaFinal" => "449" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28495077" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: findings from the PRISM study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.S. Shim" 1 => "H. Kim" 2 => "J.W. Kwon" 3 => "S.Y. Park" 4 => "S. Kim" 5 => "B.K. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.waojou.2023.100848" "Revista" => array:6 [ "tituloSerie" => "World Allergy Organ J" "fecha" => "2023" "volumen" => "16" "numero" => "12" "paginaInicial" => "100848" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/38093952" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The response to biologics is better in patients with severe asthma than in patients with asthma-COPD overlap syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "L. Pérez de Llano" 1 => "D. Dacal Rivas" 2 => "N. Marina Malanda" 3 => "V. Plaza Moral" 4 => "J.A. Gullón Blanco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/JAA.S338467" "Revista" => array:6 [ "tituloSerie" => "J Asthma Allergy" "fecha" => "2022" "volumen" => "15" "paginaInicial" => "363" "paginaFinal" => "369" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35330786" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world effectiveness of benralizumab among patients with asthma and concomitant chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.D. Carstens" 1 => "D.J. Maselli" 2 => "E.E. Cook" 3 => "F. Mu" 4 => "J. Chen" 5 => "D. Yang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/COPD.S468887" "Revista" => array:6 [ "tituloSerie" => "Int J Chron Obstruct Pulmon Dis" "fecha" => "2024" "volumen" => "19" "paginaInicial" => "1813" "paginaFinal" => "1818" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/39129964" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/unassign/S0300289624004095/v1_202410291634/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/03002896/unassign/S0300289624004095/v1_202410291634/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289624004095?idApp=UINPBA00003Z" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 3 | 1 | 4 |
| 2024 October | 42 | 28 | 70 |
